Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

dezamizumab

A fully humanized monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Upon intravenous administration, dezamizumab binds to SAP in amyloid deposits, thereby activating compliment and triggering the rapid clearance of amyloid by macrophage-derived multinucleated giant cells. SAP is a universal component of amyloid deposits and contributes to the pathogenesis of amyloidosis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-SAP mAb anti-SAP monoclonal antibody
Code name:	GSK 2398852 GSK-2398852 GSK2398852

dezamizumab

Search NCI's Drug Dictionary